Хлебные крошки
- Главная
-
Аналитика
-
Акции
Акции внутренные
INVO Bioscience, Inc. INVO
$0.36
+$0.01 (1.40%)
На 18:04, 12 мая 2023
Ранг: 3
Ключевые показатели
-
Marketcap
4335294.00000000
-
week52high
1.85
-
week52low
0.31
-
Revenue
822196
-
P/E TTM
-1
-
Beta
1.22387500
-
EPS
-0.89000000
-
Last Dividend
0.00000000
-
Next Earnings Date
15 мая 2023 г. в 10:59
Описание компании
INVO Bioscience, Inc., a commercial-stage fertility company, provides assisted reproductive technology solutions worldwide. Its flagship product is the INVOcell, a medical device that allows fertilization and early embryo development to take place in vivo within the woman's body. The company was founded in 2007 and is based in Sarasota, Florida.
Рекомендации
аналитиков
Рекомендации аналитиков
| Grading company | New grade | Previous grade | Recommendation date |
|---|---|---|---|
| Roth Capital | Neutral | Buy | 13 апр 2022 г. |
| Maxim Group | Buy | 19 янв 2022 г. | |
| Roth Capital | Buy | Buy | 18 авг 2021 г. |
Свежие комментарии
Свежие комментарии
Оставьте свой голос
Оставьте свой голос
Анонимное голосование
Будет ли рост российского рынка к концу года?
-
Да
87% -
Нет
12%
Проголосовал 8 человек
Новостная лента
компании
Insider Summary
Insider Summary
| Reporting Name | Acquistion/Disposition | Owned | Transacted | Transaction Date |
|---|---|---|---|---|
| Messina Rebecca | A | 23045 | 9868 | 01 июн 2022 г. |
| Goren Andrea | A | 129015 | 52632 | 01 июн 2022 г. |
| Campbell Michael Jos. | A | 75762 | 10526 | 01 июн 2022 г. |
| Segal Jeffrey | A | 28220 | 9211 | 01 июн 2022 г. |
| Szot Matthew K | A | 39175 | 14474 | 01 июн 2022 г. |
| DAVIS TRENT D | A | 33622 | 11184 | 01 июн 2022 г. |
| Ryan Barbara | A | 22991 | 10526 | 01 июн 2022 г. |
| Shum Steve | A | 128420 | 58885 | 01 июн 2022 г. |
| Doody Kevin | D | 0 | 177306 | 01 июн 2022 г. |
| DAVIS TRENT D | A | 10771 | 10771 | 15 янв 2022 г. |
Новостная лента
INVO Bioscience, Inc. (INVO) Q3 2022 Earnings Call Transcript
Seeking Alpha
14 ноя 2022 г. в 21:18
INVO Bioscience, Inc. (NASDAQ:INVO ) Q3 2022 Earnings Conference Call November 14, 2022 4:30 PM ET Company Participants Robert Blum - Lytham Partners, IR Steven Shum - Chief Executive Officer Mike Campbell - Chief Operating Officer and VP, Business Development Andrea Goren - Chief Financial Officer Conference Call Participants John Heerdink - Vista Partners LLC Operator Good day. And welcome to the INVO Bioscience Reports on the Third Quarter 2022 Financial Results Call.
INVO Bioscience, Inc's (INVO) CEO Steve Shum on Q2 2022 Results - Earnings Call Transcript
Seeking Alpha
15 авг 2022 г. в 21:41
INVO Bioscience, Inc. (NASDAQ:INVO ) Q2 2022 Earnings Conference Call August 15, 2022 4:30 PM ET Company Participants Robert Blum – Investor Relations Steve Shum – Chief Executive Officer Mike Campbell – Chief Operating Officer and Vice President of Business Development Andrea Goren – Chief Financial Officer Conference Call Participants John Heerdink – Vista Partners LLC Curtis Thom – Paulson Operator Good day, and welcome to the INVO Bioscience's Reports Second Quarter 2022 Financial Results Call. All participants will be in listen-only mode.
INVO Bioscience, Inc. (INVO) CEO Steven Shum on Q1 2022 Results - Earnings Call Transcript
Seeking Alpha
16 мая 2022 г. в 21:19
INVO Bioscience, Inc. (NASDAQ:INVO ) Q1 2022 Earnings Conference Call May 16, 2022 4:30 PM ET Company Participants Robert Blum - Lytham Partners, LLC, IR Steven Shum - CEO Michael Campbell - COO and VP, Business Development Andrea Goren - CFO Conference Call Participants John Heerdink - Vista Partners Operator Good day, and welcome to the INVO Bioscience First Quarter 2022 Financial Results Conference Call. Today all participants will be in a listen-only mode.
INVO Bioscience, Inc. (INVO) CEO Steven Shum on Q4 2021 Results - Earnings Call Transcript
Seeking Alpha
31 мар 2022 г. в 22:12
INVO Bioscience, Inc. (INVO) CEO Steven Shum on Q4 2021 Results - Earnings Call Transcript
INVO Bioscience to Report Fourth Quarter and Fiscal Year 2021 Financial Results on Thursday, March 31, 2022
PRNewsWire
24 мар 2022 г. в 16:15
Financial results to be released after market close; Conference call to be conducted at 4:30 pm ET SARASOTA, Fla. , March 24, 2022 /PRNewswire/ -- INVO Bioscience, Inc. (NASDAQ: INVO), a commercial-stage fertility company focused on expanding access to advanced treatment worldwide with its INVOcell® medical device and the IVC procedure it enables, will report financial results for its fourth quarter and fiscal year 2021, ended December 31, 2021, after the market close on Thursday, March 31, 2022.